Analysis of PAH-DNA adducts and gene polymorphisms of CYP1A1 and GSTM1 in lymphoma patients
10.3760/cma.j.issn.1009-9921.2014.04.010
- VernacularTitle:淋巴瘤患者多环芳烃-DNA加合物及代谢酶基因细胞色素氧化酶P4501A1与谷胱苷肽硫转移酶M1基因多态性的研究
- Author:
Yanbo LI
;
Wei WANG
;
Jie YANG
;
Fang HOU
;
Jiaxiu LIU
- Publication Type:Journal Article
- Keywords:
Lymphoma;
PAH-DNA;
CYP1A1;
GSTM1;
Genetic polymorphisms
- From:
Journal of Leukemia & Lymphoma
2014;23(4):228-231,243
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the relationship between PAH-DNA adducts and CYP1A1,GSTM1 gene polymorphisms and lymphoma.Methods PAH-DNA adducts from bone marrow of lymphoma patients and control cases were determined by competitive ELISA.The genotypes of both CYP1A1 and GSTM1 were detected by PCR-based restriction fragment length polymorphisms (PCR-RELP).Results The level of PAH-DNA adducts in lymphoma patients [(2 498±1 250) pg/ml] was significantly higher than that in control [(1 882±797) pg/ml] (t =0.006,P < 0.05).CYP1A1 mutant genotype and GSTM1 null genotype had increased risk of lymphoma,with OR being 1.36 (95 % CI 0.56-3.31,P > 0.05),4.03 (95 % CI 1.51-10.76,P < 0.05),respectively.GSTM1 null genotype individuals with PAH-DNA level higher (or equal) than 2 200 pg/ml had increased risk of lymphoma.Conclusions The content of PAH-DNA adducts and the occurrence of lymphoma may have a certain correlation.GSTM1 null genotype may be linked to lymphoma and increase the risk.